NCT03347123View on ClinicalTrials.gov

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

January 29, 2021

Study Completion Date

January 29, 2021

Conditions
Solid Tumors
Interventions
DRUG

Epacadostat

Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.

DRUG

Nivolumab

Nivolumab at the protocol-specified dose and schedule.

DRUG

Ipilimumab

Ipilimumab at the protocol-specified dose and schedule.

DRUG

Lirilumab

Lirilumab at the protocol-specified dose and schedule.

Trial Locations (5)

27710

Duke University Medical Center, Durham

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

90025

The Angeles Clinic and Research Institute, Los Angeles

90404

John Wayne Cancer Institute, Santa Monica

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY